GT Biopharma, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -264.8% | -264.8% | -180.3% |
| FY2022 | -178.0% | -178.0% | -124.8% |
| FY2023 | -101.6% | -101.6% | -53.8% |
| FY2024 | 788.1% | 788.1% | -311.0% |
| FY2025 | -490.0% | -490.0% | -349.8% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -264.8% | -264.8% | -180.3% |
| FY2022 | -178.0% | -178.0% | -124.8% |
| FY2023 | -101.6% | -101.6% | -53.8% |
| FY2024 | 788.1% | 788.1% | -311.0% |
| FY2025 | -490.0% | -490.0% | -349.8% |